Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | CYP2A13 | Q16696 | 4/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27010364 | 0.94 | PTGDR2 (0.43) | PTGDR2TSHRALDH1A1CYP2A13OPRM1 | |
| SCHEMBL27010304 | 0.90 | PTGDR2 (0.45) | PTGDR2TSHRALDH1A1CYP2A13NPC1 | |
| SCHEMBL27010235 | 0.88 | PTGDR2 (0.45) | PTGDR2TSHRALDH1A1CYP2A13OPRM1 | |
| SCHEMBL26620028 | 0.87 | PTGDR2 (0.46) | PTGDR2TSHRALDH1A1CYP2A13OPRM1 | |
| SCHEMBL24315785 | 0.87 | PTGDR2 (0.42) | PTGDR2TSHRALDH1A1OPRM1OPRK1 | |
| SCHEMBL27010238 | 0.87 | CYP2D6 (0.43) | PTGDR2TSHRALDH1A1CYP2A13CYP2D6 | |
| SCHEMBL26620030 | 0.85 | PTGDR2 (0.48) | PTGDR2TSHRALDH1A1CYP2A13OPRM1 | |
| SCHEMBL24315678 | 0.83 | PTGDR2 (0.43) | PTGDR2TSHRALDH1A1CYP2A13OPRM1 | |
| SCHEMBL26620324 | 0.83 | PTGDR2 (0.45) | PTGDR2TSHRALDH1A1CYP2A13OPRM1 | |
| SCHEMBL24315684 | 0.83 | PTGDR2 (0.42) | PTGDR2TSHRALDH1A1CYP2D6NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | C 4 Therapeutics, Inc. (US) | 2024-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | NFATC1, CTSS, MMP12 | PTGDR2 2093/4885TSHR 2445/4885ALDH1A1 2267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.